Source: Global Legal Chronicle

Kojin: Kojin Therapeutics' $60 Million Series A Financing

Goodwin Procter LLP advised Cathay Health, Polaris Partners, and Newpath Partners on the deal. Cathay Health, Polaris Partners, and Newpath Partners lead the Kojin Therapeutics' $60 Million Series [...]

Read full article »

Kojin's Competitors | Kojin's News | Kojin's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Chairman & CEO

Harvey J. Berger

CEO Approval Rating

85/100

Kojin is a Massachusetts-based biotechnology company that researches and develops cell-state biological therapeutics for the treatment of cancer, ischemia and fibrosis.